CuraVac gears up to the next level:  
1st MG patients injected in March 2015  
Creation of an Independent Advisory Board

Rixensart (Belgium), 24 June 2014 - CuraVac, a biotech specialized in therapeutic vaccines for autoimmune diseases announces strategic advancements.

1- Creation of Myasterix and first clinical trials

CuraVac created the Myasterix consortium in 2013 after successfully applying to the European Union Seventh Framework Programme for funding for the clinical trials for the therapeutic vaccine for Myasthenia Gravis. This consortium is composed of 4 European companies (Aepodia, Inserm Transfert, piChem and CuraVac) and the Leiden University Medical Center (LUMC). The clinical trials will begin in March 2015 at the Leiden University Medical Center. LUMC is the reference center for the treatment of Myasthenia Gravis in the Netherlands.

The project represents a total budget of USD $10 m over 5 years and is 80% financed in the context of the 7th Framework Project of the European Union for technological research and development (FP7).

2- CuraVac’s Independent Advisory Board

CuraVac is proud to announce the creation of an Independent Advisory Board and to welcome to this board Didier Hoch and Jean-Paul Prieels.

« At less than a year from Phase 1 of the therapeutic vaccine for Myasthenia Gravis, the acceptance of these two specialists to join CuraVac’s IAB is a strong sign for our biotech and its partners. Having been successful in acquiring financial support through the FP7 and won the Catyzer award at BioVision 2014, this is further proof that CuraVac is continuing its development in a systematic and durable manner. Didier Hoch and Jean-Paul Prieels have both been at the head of large
pharmaceutical divisions at Sanofi Pasteur and GSK » says Dr. Stéphane Huberty, CEO at CuraVac.

Dr. Didier Hoch is the CEO of BIOVISION, the World Life Sciences Forum. He is a medical doctor and has more than 25 years’ experience in the pharmaceutical and vaccine industries. From 2000 to 2010, he was at the head of Sanofi Pasteur MSD, vaccine market leader, responsible for the development and distribution of several vaccines, most notably Gardasil. From 2003 to 2009, he was the chairman of the Vaccines Europe.

Since 2009, Didier Hoch has been the chair of the Health and Science Committee of MEDEF and he is a member of the board of several biotech companies.

Dr. Jean-Paul Prieels, Ph.D, served as a Senior Vice President of Research and Development at GlaxoSmithKline Biologicals (now GSK Vaccines) until January 2011. Dr. Prieels joined GlaxoSmithKline Biologicals in 1987 as an Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart, Belgium. His career spans from basic research to process and product development. He was instrumental in developing several commercially available vaccines, such as rotavirus, human papilloma virus (HPV), pneumococcal conjugates and others. He served as Head of Research at GSK Vaccines. He serves as a Director of Vaximm AG. Since 2007, he has been a Member of the Scientific Advisory Board of the Singapore Bioprocessing Technology Institute. He serves as Chairman of the Board at Immune Health and he was also a Board member of Henogen from 2000 to 2008.

3- Myasterix wins the Catalyzer Award for « Immunotherapies & Vaccines » at Biovision

On 6 June last, CuraVac won the Catalyzer Award for “Immunotherapies & Vaccines” organized by Biovision 2014 for the Myasterix project (Therapeutic Vaccine for Myasthenia Gravis). BIOVISION is globally renowned and brings together researchers, politicians, investors and entrepreneurs from start-ups to multinationals every year in Lyon (France). These pluridisciplinary decision makers get together to think about future advancements in the life sciences.

About CuraVac

CuraVac is a virtual biotech active in the USA and Europe. Its goal is to cure or significantly improve the state of patients suffering from autoimmune diseases with a simple course of treatment consisting of 3 injections of a perfectly targeted therapeutic vaccine. It coordinates a network of sub-contractors, who have the
task of manufacturing the vaccine to human standards and conducting animal testing and clinical trials. This highly flexible organization enables CuraVac to be quick to react and to spend funds only on what counts in order to maximize results for the patients, society and stakeholders.

Vaccinate and cure patients with autoimmune diseases rather than medicate them for life

CuraVac’s therapeutic vaccine enables the body to reprogram and rebalance the immune system. This innovative approach is based on complementary peptide antigens discovered by Prof. J. Edwin Blalock (University of Alabama at Birmingham), CSO at CuraVac. This curative approach is centered on the patient and the cure of its disease as opposed to an approach whereby the disease and its symptoms are managed over the long term.

CuraVac is currently concentrating on Myasthenia Gravis (MG) and Multiple Sclerosis (MS) but this developmental platform has also proven effective in the treatment of Guillain-Barre (GBS) in rats. In the USA, Europe and Japan alone, 250,000 people are diagnosed with MG, 1.25 million people suffer from MS and more than 50 million people have an autoimmune disease.

Created in 2002, this biotech has raised $12 million in non-dilutive capital and established its credibility: “We raise funds and optimize their use but ultimately we remove all the risks related to an investment in a revolutionary therapeutic technique” explains Dr. Stéphane Huberty, CEO of CuraVac.

For more information, contact us:

Dr. Stéphane Huberty, MD
CEO of CuraVac

Nicolas Havelange,
COO of CuraVac

Avenue de Villefranche 80, B-1330 Rixensart, Belgium
Tel : +32 2 686 04 45
Mail : info@curavac.com
Web : www.curavac.com